Johanna Mercier, Chief Commercial and Corporate Affairs Officer at Gilead Sciences, Inc.. Biography, career history and compensation sourced from Gilead Sciences, Inc. SEC filings and official company website.
About
Johanna Mercier is Gilead's Chief Commercial and Corporate Affairs Officer, responsible for driving top-line revenue growth and expanding access to Gilead's therapies across virology, oncology and inflammation. In late 2025 she took on additional responsibility for the company's public affairs and government affairs functions worldwide.
She has been central to Gilead's portfolio diversification and led the launch of a novel long-acting option for HIV prevention as well as the rapid launch and global access efforts for Gilead's COVID-19 antiviral during the pandemic. Before joining Gilead in 2019, Ms. Mercier spent 25 years at Bristol Myers Squibb in senior leadership roles across the U.S. and international markets.
Roles
Gilead Sciences, Inc.
Chief Commercial and Corporate Affairs Officer · Current role
2019–present
Bristol Myers Squibb
Senior leadership roles across U.S. and international markets · Spent 25 years at Bristol Myers Squibb before joining Gilead.
—
Bristol Myers Squibb
President and Head, Large Markets division · Large Markets division included the United States, France, Germany and Japan; most recent BMS role before joining Gilead.
—
External Roles
Arcus Biosciences
Member, Board of Directors
—
Neurocrine Biosciences
Member, Board of Directors
—
USC Leonard D. Schaeffer Center for Health Policy and Economics
Board Member
—
Fixed Compensation
FY 2025
Salary
$1,182,269
ComponentAnnual base salary (FY2025)
All other compensation
$102,980
Perquisites and other personal benefits$80,498
Contributions to 401(k) plan$15,000
Insurance premiums$7,482
Total compensation
$9,300,643
Performance Compensation
Data from FY 2025
Cash incentive
Annual cash incentive
$2,150,901
FormNon-Equity Incentive Plan Compensation
Target Opportunity
—
Target incentive opportunity$1,189,000 (100% of salary)
Corporate performance factor134%
Individual performance factor135%
Maximum payout200% of target
Stock awards
Stock awards
$4,564,517
FormPerformance shares (50% of target LTI) and restricted stock units (25% of target LTI)
Performance shares metricRelative Total Shareholder Return (TSR) and multi-year EPS growth, earned over three years
RSU vestingOver four years
Option awards
$1,299,976
FormStock options
Weight of target LTI25%
VestingOver four years, beginning one year after grant with quarterly vesting thereafter